Supplementary Table S9. Summary of anti-drug antibody against SAR441000 and cemiplimab

	Escalation Monotherapy	Escalation Combination	Expansion Combination
ADA against SAR441000			
N	12	10	29
Number of patients ADA positive at baseline, n (%)	0	0	0
Number of patients ADA negative at baseline, n (%)	9 (75.0)	10 (100)	18 (62.1)
Number of ADA positive patients, n (%)	0	1 (10)	2 (6.9)
ADA incidence, %	0	10	6.9
ADA against cemiplimab			
N	–	10	25
Number of patients ADA positive at baseline, n (%)	–	0	0
Number of patients ADA negative at baseline, n (%)	–	10 (100)	20 (80.0)
Number of ADA positive patients, n (%)	–	1 (10)	0
ADA incidence, %	–	10	0

ADA, anti-drug antibody; *N/n*, number of patients.